For example, both p.L858R mutation and exon 19 deletion of epidermal growth factor receptor (EGFR) gene are highly affected when treating lung cancer patients, since the patients who carry these mutations benefit from EGFR tyrosine kinase inhibitors (TKI) [2]. The gene discussed is EGFR; the disease is lung carcinoma.